Get started
Author

Tuğçe Telli

Observed names: T Telli, T. Telli, Telli, T., Telli, Tugce, Tugce Telli, Tuğçe TELLİ
ORCID: 0000-0002-9939-282X
Observed ORCID: 0000-0002-9939-282X
OpenAlex ID: A5081830988
Combining PSMA-PET and PROMISE to re-define disease stage and risk in patients with prostate cancer: a multicentre retrospective study
2024 · Madeleine J Karpinski, Johannes Hüsing, et al. · The Lancet Oncology · 91
Unspecific 18 F-PSMA-1007 Bone Uptake Evaluated Through PSMA-11 PET, Bone Scanning, and MRI Triple Validation in Patients with Biochemical Recurrence of Prostate Cancer
2022 · Robert Seifert, Tugce Telli, et al. · Journal of Nuclear Medicine · 77
PDF
Is 18 F-FDG PET Needed to Assess 177 Lu-PSMA Therapy Eligibility? A VISION-like, Single-Center Analysis
2022 · Robert Seifert, Tugce Telli, et al. · Journal of Nuclear Medicine · 45
PDF
Safety and Efficacy of Extended Therapy with [177Lu]Lu-PSMA: A German Multicenter Study
2024 · Robert Seifert, Tugce Telli, et al. · Journal of Nuclear Medicine · 39
PDF
The Complementary Role of 68Ga-DOTATATE PET/CT in Neuroblastoma
2020 · Tuğçe Telli, Eser Lay Ergün, et al. · Clinical Nuclear Medicine · 27
Predictive factors of tumor sink effect: Insights from 177Lu-Prostate-specific membrane antigen therapy
2021 · Murat Tuncel, Tuğçe Telli, et al. · Annals of Nuclear Medicine · 21
Prognostic value of [18F]FDG- and PSMA-PET in patients evaluated for [177Lu]Lu-PSMA therapy of mCRPC
2025 · Tugce Telli, Leonor Lopes, et al. · European Journal of Nuclear Medicine and Molecular Imaging · 18
Prognostic Implications of PET-Derived Tumor Volume and Uptake in Patients with Neuroendocrine Tumors
2023 · Manuel Weber, Tugce Telli, et al. · Cancers · 18
PDF
Standardized PSMA-PET Imaging of Advanced Prostate Cancer
2023 · R. Seifert, A. Gafita, et al. · Seminars in Nuclear Medicine · 15
Prognostic factors of overall and prostate‐specific antigen‐progression‐free survival in metastatic castration‐resistant prostate cancer patients treated with 177Lu‐PSMA‐617. A single‐center prospective observational study
2023 · Tugce Telli, Murat Tuncel, et al. · The Prostate · 15
PDF
The Added Value of Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography to Magnetic Resonance Imaging for Local Staging of Prostate Cancer in Patients Undergoing Radical Prostatectomy
2024 · Timo F.W. Soeterik, Joris G. Heetman, et al. · European Urology Oncology · 13
What Role Does PET/MRI Play in Musculoskeletal Disorders?
2023 · Tugce Telli, Mélanie Desaulniers, et al. · Seminars in Nuclear Medicine · 13
The association of quantitative PSMA PET parameters with pathologic ISUP grade: an international multicenter analysis
2024 · Timo F. W. Soeterik, Joris G. Heetman, et al. · European Journal of Nuclear Medicine and Molecular Imaging · 12
PDF
PSMA-PET follow-up to assess response in patients not receiving PSMA therapy: Is there value beyond localization of disease?
2024 · Alina T. Küper, David Kersting, et al. · Theranostics · 11
PDF
External validation of nomograms including PSMA PET information for the prediction of lymph node involvement of prostate cancer
2025 · Tessa D. Van Bergen, Arthur J. A. T. Braat, et al. · European Journal of Nuclear Medicine and Molecular Imaging · 10
PDF
Analysing the tumor transcriptome of prostate cancer to predict efficacy of Lu-PSMA therapy
2023 · Analena Handke, Claudia Kesch, et al. · Journal for ImmunoTherapy of Cancer · 9
PDF
Activity of Lutetium-177 Prostate-specific Membrane Antigen and Determinants of Outcomes in Patients with Metastatic Castration-resistant Prostate Cancer Previously Treated with Cabazitaxel: The PACAP Study
2024 · Ronan Flippot, Tugce Telli, et al. · European Urology Oncology · 6
Prognostic value of PSMA PET/CT-Based local staging in predicting biochemical recurrence after radical prostatectomy
2025 · Vera Sweere, Alexandra Bruins Slot, et al. · European Journal of Nuclear Medicine and Molecular Imaging · 5
PDF
Prognostic PSMA-PET PROMISE nomograms for patients with prostate cancer.
2024 · Wolfgang Peter Fendler, Madeleine J. Karpinski, et al. · Journal of Clinical Oncology · 3
Imaging of Cardiac Fibrosis: How Far Have We Moved From Extracellular to Cellular?
2024 · Tugce Telli, Atefeh Hosseini, et al. · Seminars in Nuclear Medicine · 3
Clinical Impact of PET Imaging in Patients With Metastatic Prostate Cancer
2020 · Murat Tuncel, Meltem Çağlar Tuncalı, et al. · Clinical Nuclear Medicine · 3
Colonic Visualization of 99mTc-DMSA Due to Enterovesical Fistula
2020 · Tuğçe Telli, Gürsan Kaya, et al. · Clinical Nuclear Medicine · 2
PSMA-PET response under [177Lu]Lu-PSMA therapy: Comparison of RECIST, PERCIST, PPP, adapted PCWG4 and RECIP criteria
2026 · Tugce Telli, Madeleine J. Karpinski, et al. · European Journal of Nuclear Medicine and Molecular Imaging · 1
PDF
Nodal maximum standardised uptake value improves PSMA ‐ PET / CT ‐based nodal staging in intermediate‐ and high‐risk prostate cancer
2026 · Alexandra S. Bruins Slot, Vera Sweere, et al. · British Journal of Urology · 1
Transcriptomic Profiling of the Tumor Immune Microenvironment Reveals Prognostic Markers in mCRPC Patients Treated with LuPSMA Therapy
2025 · Analena Handke, Leonor Lopes, et al. · Theranostics · 1
PDF
Works count: 46
Citation count: 461
H-index: 12
I10-index: 15
Year
Topic
Type